Navigation Links
WuXi PharmaTech Completes Acquisition of AppTec
Date:1/31/2008

SHANGHAI, China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX) today announced the completion of its acquisition of AppTec Laboratory Services, Inc., a US-based service provider for the biopharmaceutical and medical device industries. AppTec offers testing, contract research and development, and cGMP biologics manufacturing services from a highly differentiated, fully integrated platform.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The combined company brings together complementary service offerings and expertise to create a broad platform covering both chemistry and biologics, which allows WuXi PharmaTech to provide value-added services to our customers in the pharmaceutical, biotechnology and medical device industries.

"We are pleased to have completed this significant acquisition which immediately adds biologics capabilities and expertise to WuXi PharmaTech's existing capabilities, gains a significant U.S. operational footprint for WuXi PharmaTech and expands our U.S. customer base, with further opportunities to increase our market position," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This acquisition further solidifies our leadership position as the premier and preferred drug R&D service partner for pharmaceutical, biotechnology and medical device companies."

"The management teams and dedicated employees of both companies are very enthusiastic about the prospects of the combined company," commented Mr. Edward Hu, COO of WuXi PharmaTech. "This is an acquisition of capabilities that we believe will drive our future growth by positioning WuXi as a high quality global drug R&D service collaborator with both small and large molecules expertise."

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2007, its 80 customers included nine of the world's top ten pharmaceutical companies by revenue. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Hai Mi, Ph.D.

Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd.

Tel: +86-21-5046-3726

Fax: +86-21-5046-3718

Email: mi_hai@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
2. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
3. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
4. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
5. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
6. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
7. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
8. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
9. WuXi PharmaTech Announces Second Quarter 2007 Results
10. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
11. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... THOUSAND OAKS, Calif. , Dec. 2, 2016 ... AGN ) today announced the submission of a ... for ABP 215, a biosimilar candidate to Avastin ® ... biosimilar application submitted to the EMA. "The ... milestone as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , ... industries is anticipated. Nanotechnology will be applied at all stages ... diagnostic applications in clinical trials. Many of the assays based ...
(Date:12/2/2016)... , ... December 01, 2016 ... ... will share findings demonstrating the value of DNA microarray comparative genomic hybridization ... year’s San Antonio Breast Cancer Symposium. Using molecular test results from tumors ...
(Date:12/2/2016)... ... 01, 2016 , ... PhUSE will build on the huge ... Single Day Events (SDE) to organize a multiple-day US conference. The first annual ... of the pharmaceutical and life sciences industry will cover industry standards, data science, ...
Breaking Biology Technology:
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
Breaking Biology News(10 mins):